EVP Jenne Kyle sold 37,277 shares at $75.50–$76.30 for $2.8M, reducing stake 69.5% to 16.4K shares
Jenne Kyle, EVP and Chief Global Product Strategy Officer, executed 2 separate sales totaling 37,277 shares for $2,827,324.68 at a blended average price of $75.85. This represents a 69.5% reduction in her post-transaction holdings to 16,389 shares. The transaction occurred at prices above the current market level of $74.79 and near the 52-week high of $86.50, yet the stock has declined 13.5% from that peak and 11.8% over the prior 30 days. Notably, IONIS Pharmaceuticals generated 33.8% annual revenue growth in the latest period but remains unprofitable, with a negative net income of $-128,606,000.00 over its most recent full fiscal year—a context in which a substantial reduction in equity stake by a senior product strategy executive warrants attention.